7 FDA Headlines You Missed in January 2026 HCPLive The FDA just changed the game for peptides. April 2026 The FDA is reviewing Category 2 peptides for potential removal from restricted status. Full approval for some peptides may be Buy GHK Cu 50mg & 100mg Copper Tripeptide Koi Peptides GHK Cu FDA Approval Status 2026: Not Approved 2026 FDA Peptide Reclassification Purefico Medspa and Therapy The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what